Detection of renal failure by cardiac implantable medical device

• US 7,400,920 B1
• Filed: 08/11/2005
• Issued: 07/15/2008
• Est. Priority Date: 08/11/2005
• Status: Expired due to Fees

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Gill, Jong, Bornzin, Gene A.
• Primary Examiner(s): Layno; Carl H.
• Assistant Examiner(s): PATEL, NATASHA
• Application Number:
  US11/202,553
• Time in Patent Office: 1,069 Days
• Field of Search: 607/25, 600/509, 600/513, 600/516
• US Class Current: 600/516
• CPC Class Codes: A61B 5/201 Assessing renal or kidney functions
• CPC Class Codes: A61B 5/364 Detecting abnormal ECG interval, e.g. extrasystoles, ectopic heartbeats

Abstract

Morphological features within electrical cardiac signals are tracked and changes in features are monitored to detect renal failure. The morphological feature may be an interval between corresponding polarization events such as the interval between QRS-complexes and peaks of corresponding T-waves (QTmax interval); the interval between QRS-complexes and ends of corresponding T-waves (QTend interval); or the interval between P-waves and corresponding QRS-complexes (PR interval). The feature may also be the elevation of a cardiac signal segment between corresponding polarization events, such as QRS-complexes and corresponding T-waves (ST segment); a duration of a polarization event, such as a QRS-complex (QRS width); or an amplitude of a polarization event, such as a T-wave (T-wave amplitude). The change in the feature may comprise a decrease in QTmax intervals, a decrease in QTend intervals, a deviation in ST segment elevation, an increase in QRS width, an increase in PR interval or a deviation in T-wave amplitude.

Claims

1. A method of detecting renal failure comprising:

tracking intervals between QRS-complexes and ends of corresponding T-waves (QTend intervals), intervals between QRS-complexes and peaks of corresponding T-waves (QTmax intervals) and elevations of a segment of a cardiac signal between QRS-complexes and corresponding T-waves (ST segment elevations), within electrical cardiac signals obtained using an implantable medical device; and

detecting renal failure, as opposed to myocardial ischemia, hypoglycemia or hyperglycemia when there is a deviation in ST segment elevation in combination with a decrease in QTend interval and a decrease in QTmax interval.

2. A method of detecting renal failure comprising:

for each of at least two different PQRST complexes within an intracardiac electrogram obtained using an implantable medical device, tracking two different intervals between QRS complexes and corresponding T waves; and

detecting renal failure if each of the two different intervals decrease by a respective amount.

3. The method of claim 2 wherein one of the two different intervals is an interval between QRS-complexes and ends of corresponding T-waves (QTend intervals) and its respective amount is a percentage of a baseline QTend interval.

4. The method of claim 2 wherein one of the two different intervals is an interval between QRS-complexes and peaks of corresponding T-waves (QTmax intervals) and its respective amount is a percentage of a baseline QTmax interval.

5. The method of claim 2 further comprising delivering a pacing pulse to induce an evoked response element of the PQRST complexes.

6. The method of claim 2 further comprising calculating a renal failure burden representative of a proportion of time renal failure is detected.

7. A method of detecting renal failure comprising:

for each of at least two different PQRST complexes within an intracardiac electrogram obtained using an implantable medical device, tracking two different intervals between QRS complexes and corresponding T waves and tracking another morphological feature within the two different PQRST complexes; and

detecting renal failure if each of the two different intervals decrease by a respective amount and the other morphological feature changes.

8. The method of claim 7 wherein the other morphological feature comprises the elevation of a segment of a cardiac signal between QRS-complexes and corresponding T-waves (ST segment) and a change comprises an increase or decrease in the ST segment with respect to a baseline elevation.

9. The method of claim 7 wherein the other morphological feature comprises the peak amplitude of a polarization event (T-wave amplitude) and a change comprises an increase or a decrease in the T-wave amplitude with respect to a baseline amplitude.

10. The method of claim 7 wherein the other morphological feature comprises the interval between P-waves and corresponding QRS-complexes (PR interval) and a change comprises an increase in the PR interval with respect to a baseline interval.

11. The method of claim 7 wherein the other morphological feature comprises the width of QRS-complexes and a change comprises an increase in the QRS width with respect to a baseline width.